Targacept, Inc. (TRGT.O)
21.83USD
4:00pm EST
$-0.02 (-0.09%)
$21.85
$21.91
$22.20
$21.50
203,243
491,753
$24.50
$2.00
TRGT.O
About
Overall
| Beta: | 3.78 |
| Market Cap (Mil.): | $605.26 |
| Shares Outstanding (Mil.): | 27.70 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| TRGT.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 12.05 | 4.64 |
| EPS (TTM): | 37.94 | -- | -- |
| ROI: | -22.75 | 1.33 | 2.79 |
| ROE: | -33.78 | 2.17 | 3.51 |
UPDATE 2-Astra drug gets limited U.S. okay for depression
* U.S. FDA calls for more information about monotherapy use
Astra to buy Targacept drug
LONDON (Reuters) - AstraZeneca has bought rights to an experimental antidepressant from Targacept in a deal worth up to $1.24 billion (748 million pounds), boosting its pipeline and slapping an endorsement on its U.S. biotech partner's drug.
Astra to pay up to $1.24 billion for Targacept drug
LONDON (Reuters) - AstraZeneca has bought rights to an experimental antidepressant from Targacept in a deal worth up to $1.24 billion, boosting its pipeline and slapping an endorsement on its U.S. biotech partner's drug.
UPDATE 5-Astra to pay up to $1.24 bln for Targacept drug
* TC-5214 will help fill AstraZeneca's late-stage pipeline
HEADLINE STOCKS-Some U.S. stocks on the move on Oct. 8
(Updates to afternoon trading, adds Mosaic, Plains Exploration and Gardner Denver. Updates NCR)
UPDATE 1-Repros, Targacept to offer shares at discount
Oct 8 (Reuters) - Shares of Repros Therapeutics Inc and Targacept Inc fell sharply, after the companies said they plan to raise money by selling shares at a discount.
HEADLINE STOCKS-Some U.S. stocks on the move on Oct. 8
(Updates to after the open, adds L-3, Tractor Supply, Liz Claiborne, Macy's, Aeropostale, Abercrombie, TJX, Gap, Target, Gymboree, International Speedway, Targacept)
UPDATE 2-Targacept's depression drug meets mid-stage trial goals
BANGALORE, July 15 (Reuters) - Targacept Inc said its experimental depression drug, TC-5214, that was being tested as an augmentation treatment for major depressive disorder, met all the goals of a mid-stage trial, prompting a more than two-fold rise in its stock price.
UPDATE 2-AstraZeneca to further develop Targacept's ADHD drug
* Says partner AstraZeneca to further develop ADHD drug
UPDATE 2-Targacept ADHD drug meets mid-stage goal, shares up
* 50mg AZD3480 shows statistically significant improvement
Competitors
| Price | Change | |
|---|---|---|
| Sanofi-Aventis SA (SASY.PA) | €53.44 | -0.81 |
| Abbott Laboratories (ABT.N) | -- | -- |
| AstraZeneca plc (AZN.L) | £2,818.00 | -25.00 |
| Eli Lilly & Co. (LLY.N) | $35.45 | -0.26 |
| Wyeth (WYE.N) | -- | -- |
| Wyeth (WYE_p.N) | -- | -- |
| Memory Pharmaceuticals Corp. (MEMY.OQ) | -- | -- |
| Cornerstone Therapeutics, Inc. (CRTX.OQ) | $5.06 | +0.01 |
| NeuroSearch A/S (NEUR.CO) | kr.70.50 | -0.50 |
| Pfizer Inc. (PFE.N) | $18.22 | -0.19 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
